Dynamic quotes: Off
|
Company Description (as filed with the SEC)
We are a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered DNA-binding proteins for the development of novel therapeutic strategies for unmet medical needs. Our current mission is to develop ZFP Therapeutics ® through early stage clinical testing, strategically partner with biopharmaceutical companies at points of value inflection and have the partner execute late-stage clinical trials and commercial development. In the long term, our goal is to integrate marketing and development operations and to capture the value of late-stage and commercial ZFP Therapeutic products for ourselves. We, and our licensed partners, are the leaders in the research, development and commercialization of zinc finger DNA-binding proteins (ZFPs), a naturally occurring class of proteins. We have used our knowledge and expertise to develop a proprietary technology platform. ... More ...
Analyst Info |
|
| Annual EPS Est: | $-0.42 |
| Quarterly EPS Est: | -0.13 |
| PEG Ratio: | -.02 |
|
Mean Recommendation: View Summary / View All |
1 |
Data is provided by Zacks Investment Research

